NEW YORK, Oct. 18, 2019 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Achillion Pharmaceuticals, Inc. ("ACHN" or the "Company") (NASDAQ: ACHN) in connection with the proposed acquisition of the Company by Alexion Pharmaceuticals, Inc. ("ALXN") (NASDAQ: ALXN). Under the terms of the acquisition agreement, ACHN shareholders will receive $6.30 cash for each ACHN share they own.
If you own ACHN shares and wish to discuss this investigation or have any questions concerning this notice or your rights or interests, visit our website:
Or please contact:Joshua Rubin, Esq.WeissLaw LLP1500 Broadway, 16th FloorNew York, NY 10036(212) 682-3025(888) firstname.lastname@example.org
WeissLaw is investigating whether ACHN's Board acted to maximize shareholder value prior to entering into the acquisition agreement. Notably, the Company currently has two clinical stage treatments in development, including Danicopan, a lead drug candidate which has been designated as a Breakthrough Therapy by the U.S. Food and Drug Administration ("FDA") for treatment of patients with a rare blood disorder called paroxysmal nocturnal hemoglobinuria, or PNH. Receiving Breakthrough Therapy designation from the FDA indicates preliminary clinical evidence has demonstrated the drug may provide substantial improvement on at least one clinically significant endpoint compared with currently available therapy.
Given these facts, WeissLaw is concerned whether the proposed acquisition undervalues the Company, and whether all material information related to the proposed acquisition is fully and fairly disclosed.
WeissLaw LLP has litigated hundreds of stockholder class and derivative actions for violations of corporate and fiduciary duties. We have recovered over a billion dollars for defrauded clients and obtained important corporate governance relief in many of these cases. If you have information or would like legal advice concerning possible corporate wrongdoing (including insider trading, waste of corporate assets, accounting fraud, or materially misleading information), consumer fraud (including false advertising, defective products, or other deceptive business practices), or anti-trust violations, please email us at email@example.com.
View original content to download multimedia:http://www.prnewswire.com/news-releases/shareholder-alert-weisslaw-llp-investigates-achillion-pharmaceuticals-inc-300941386.html
SOURCE WeissLaw LLP